Suspension of trading

Spexis AG Share Price Swiss Exchange

Stocks

POLN

CH0106213793

Pharmaceuticals

OTC Markets Traded
Market Closed - Swiss Exchange 10:06:37 19/03/2025 pm IST 5-day change 1st Jan Change
0.0100 CHF -75.00% Intraday chart for Spexis AG -75.00% -84.62%
3 months-82.46%
6 months-77.58%
1 week-75.00%
3 months-82.46%
6 months-77.58%
Current year-84.62%
1 week 0.01
Extreme 0.01
0.04
1 month 0.01
Extreme 0.01
0.06
3 years 0.01
Extreme 0.01
1.35
5 years 0.01
Extreme 0.01
9.45
Manager TitleAgeSince
Chief Executive Officer 64 31/03/2022
Director of Finance/CFO - 01/08/2024
Director TitleAgeSince
Chairman 70 20/11/2019
Director/Board Member 65 01/06/2013
Director/Board Member 80 30/12/2021
Change 5-day change 1-year change 3-year change Capi.($)
-75.00%-75.00%-88.89%-99.22% 8L
+0.11%-1.89%+16.22%-11.26% 6.63TCr
-0.12%+3.10%+40.83%+196.27% 5.29TCr
+0.51%+37.90%+37.90%+37.90% 4.3TCr
-1.86%-4.93%-56.15%-56.66% 3.95TCr
+1.46%+1.71%+56.92%-27.51% 2.92TCr
+0.78%+1.39%+69.36%+81.90% 2.31TCr
-1.81%-16.49%+74.21%-54.90% 2.3TCr
-1.30%-6.18%+3.94%+177.59% 2.05TCr
-1.04%+0.53%+69.40%+119.96% 1.66TCr
Average -0.21%-2.11%+22.37%+36.41% 3.49TCr
Weighted average by Cap. -0.14%-1.59%+28.18%+46.09%
Logo Spexis AG
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
Employees
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B